Other languages NLS Pharmaceutics Ltd.

Equities

NLSP

CH0523961370

Market Closed - Nasdaq Other stock markets 16:30:00 2024-05-09 EDT			5-day change	1st Jan Change
0.1415 ^USD	+2.09%		+4.04%	-76.01%

04-08	Nls Pharmaceutics Ltd. Announces Resignation of Anthony S. Walsh as A Member of the Board of Directors	CI
04-03	NLS Pharmaceutics Ltd. announced that it has received $1.75 million in funding	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Nls Pharmaceutics Ltd. Announces Resignation of Anthony S. Walsh as A Member of the Board of Directors	04-08
NLS Pharmaceutics Files Plan to Regain Nasdaq Listing Compliance	02-23
NLS Pharmaceutics AG Reports Earnings Results for the Half Year Ended June 30, 2023	12-06
Sector Update: Health Care Stocks Rise in Late Afternoon Trading	12-01
Sector Update: Health Care Stocks Rise in Afternoon Trading	12-01
Top Midday Gainers	12-01
NLS Pharmaceutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value	11-16
Top Premarket Gainers	23-08-31
Sector Update: Health Care Stocks Steady Pre-Bell Monday	23-07-03
NLS Pharmaceutics' Mazindol ER Trial to Move to Phase 3	23-07-03
NLS Pharmaceutics to Proceed with Phase 3 Clinical Program for Mazindol ER for the Treatment of Narcolepsy Following FDA Review and IRB Approval of the Full Study Protocol	23-07-03
NLS Pharmaceutics Ltd. Approves Board Appointments	23-06-30
NLS Pharmaceutics Says Drug Interaction Studies of Mazindol Show 'Positive Results'	23-06-14
NLS Pharmaceutics Announces Positive Safety Data From In Vitro CYP450 and Transporter Mediated Drug-Drug Interaction Studies of Mazindol	23-06-14
NLS Pharmaceutics AG Announces Executive Changes	23-05-24
NLS Pharmaceutics AG Reports Earnings Results for the Full Year Ended December 31, 2022	23-05-05
NLS Pharmaceutics Receives Green Light from the U.S. Food and Drug Administration to Proceed with Phase 3 Clinical Program for Quilience(R) for the Treatment of Narcolepsy	23-05-02
NLS Pharmaceutics Ltd. Pharmaceutics Announces Open Label Extension Study Six-Month Data for Quilience(R) (Mazindol ER) in the Treatment of Narcolepsy Type 1 and Type 2	23-03-27
NLS Pharmaceutics Announces Completion of Open Label Extension Study with Quilience(R) (Mazindol ER) for the Treatment of Narcolepsy	23-01-30
NLS Pharmaceutics Regains Compliance With Nasdaq's Shareholders Equity Rule; Shares Rise	23-01-25

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages NLS Pharmaceutics Ltd.

Equities

NLSP

CH0523961370

Other languages

Filters